Elicio Therapeutics Financials - Benzinga

Elicio Therapeutics Inc

ELTXNASDAQ

Trade with Public

Trade with Public

$1.84

-0.04-2.13%

近くで: Sep 25, 5:00 PM EST

$1.85

0.0150.82%

時間外: Sep 25, 4:00 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Elicio Therapeutics Financials

Elicio Therapeutics (ELTX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Elicio Therapeutics Q2 EPS $(0.43) Beats $(0.54) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.43) per share which beat the analyst consensus estimate of $(0.54) by 20.37 percent. This is a 34.85 percent increase over losses of $(0.66) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q1 EPS $(0.65) Misses $(0.47) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.65) per share which missed the analyst consensus estimate of $(0.47) by 41.3 percent. This is a 25.29 percent increase over losses of $(0.87) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q4 EPS $(0.45) Beats $(0.47) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.47) by 3.23 percent. This is a 55.88 percent increase over losses of $(1.02) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q3 EPS $(0.60) Misses $(0.55) Estimate

Benzinga Newsdesk

PRO
Elicio Therapeutics Q2 EPS $(0.66) Misses $(0.65) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.65) by 1.54 percent. This is a 3.13 percent decrease over losses of $(0.64) per share

Benzinga Newsdesk

PRO
Elicio Therapeutics Q1 EPS $(0.87) Misses $(0.83) Estimate

Elicio Therapeutics (NASDAQ:ELTX) reported quarterly losses of $(0.87) per share which missed the analyst consensus estimate of $(0.83) by 4.82 percent. This is a 24.35 percent increase over losses of $(1.15) per share

Benzinga Newsdesk

© 2026 Benzinga | All Rights Reserved